AbbVie joins US government pilot to test drug discount rebates

AbbVie: AbbVie is a biopharmaceutical company that develops and commercializes therapies primarily in immunology, oncology, and neuroscience. It has been approved to participate in the federal 340B Rebate Model Pilot Program, under which it will test a claims-based rebate system for discounted pricing on specific medicines including Imbruvica, Linzess, and Vraylar starting in 2027. The company will provide participating healthcare providers with free access to the Beacon platform and related support services. US Government: The US Government, through the Health Resources and Services Administration (HRSA) within the Department of Health and Human Services, oversees the 340B drug discount program for safety-net providers serving low-income patients. It has launched a revised rebate model pilot program to shift from upfront discounts to verified post-claim rebates for select drugs. Multiple manufacturers including AbbVie have been approved to test the new approach beginning January 2027. 340B Rebate Pilot: The pilot tests a claims-submission process via the Beacon platform to verify eligibility before rebates are issued, aiming to strengthen program integrity. Pricing Transparency: The initiative seeks to improve visibility into 340B transactions and address potential duplicate discounts alongside Medicare drug price negotiations. Industry Participation: Several major pharmaceutical companies have been approved alongside AbbVie to implement the rebate model for designated products.